NYSE:CTLT - Catalent Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $41.69 +0.32 (+0.77 %) (As of 10/22/2018 10:01 AM ET)Previous Close$41.37Today's Range$41.68 - $41.6952-Week Range$36.73 - $47.87Volume200 shsAverage Volume736,903 shsMarket Capitalization$6.01 billionP/E Ratio25.96Dividend YieldN/ABeta1.4 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics and Specialty Drug Delivery segment formulates, develops, and manufactures small molecule and biologic drug products in prefilled syringes, vials and cartridges, blow-fill-seal unit doses, and injectable formats; develops biologic cell lines; manufactures biologic drug substances; and offers bioanalytical development and testing services. The Oral Drug Delivery segment formulates, develops, and manufactures oral dosage forms using proprietary and conventional drug delivery technologies, such as Zydis, OptiDose CR, OptiPact, OptiForm API and Solution Suite, Pharmatek SD Spray Drying, OptiMelt hot melt extrusion, Micron particle size reduction, and FlexDose; and provides stick pack formulation and filling, and analytical development and testing services. The Clinical Supply Services segment offers Manufacturing, packaging, labeling, storage, distribution, and inventory management for drugs and biologics clinical trials; FastChain demand-led clinical supply services; clinical e-solutions and informatics; and comparator sourcing services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey. Receive CTLT News and Ratings via Email Sign-up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNYSE:CTLT CUSIPN/A Webwww.catalent.com Phone732-537-6200 Debt Debt-to-Equity Ratio2.44 Current Ratio2.15 Quick Ratio1.79 Price-To-Earnings Trailing P/E Ratio25.96 Forward P/E Ratio24.24 P/E Growth2.46 Sales & Book Value Annual Sales$2.46 billion Price / Sales2.46 Cash Flow$3.07 per share Price / Cash13.58 Book Value$8.15 per share Price / Book5.12 Profitability EPS (Most Recent Fiscal Year)$1.59 Net Income$83.60 million Net Margins3.39% Return on Equity20.42% Return on Assets4.97% Miscellaneous Employees10,700 Outstanding Shares145,210,000Market Cap$6.01 billion Catalent (NYSE:CTLT) Frequently Asked Questions What is Catalent's stock symbol? Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT." How were Catalent's earnings last quarter? Catalent Inc (NYSE:CTLT) announced its earnings results on Tuesday, August, 28th. The company reported $0.67 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.61 by $0.06. The firm earned $685.30 million during the quarter, compared to analyst estimates of $690.69 million. Catalent had a net margin of 3.39% and a return on equity of 20.42%. The company's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.65 EPS. View Catalent's Earnings History. When is Catalent's next earnings date? Catalent is scheduled to release their next quarterly earnings announcement on Tuesday, November 6th 2018. View Earnings Estimates for Catalent. How can I listen to Catalent's earnings call? Catalent will be holding an earnings conference call on Tuesday, November 6th at 8:15 AM Eastern. Interested parties can register for or listen to the call using this link. What price target have analysts set for CTLT? 11 Wall Street analysts have issued 1 year target prices for Catalent's stock. Their forecasts range from $48.00 to $55.00. On average, they anticipate Catalent's share price to reach $49.50 in the next twelve months. This suggests a possible upside of 19.7% from the stock's current price. View Analyst Price Targets for Catalent. What is the consensus analysts' recommendation for Catalent? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalent. Who are some of Catalent's key competitors? Some companies that are related to Catalent include Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), Mylan (MYL), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Genmab A/S (GNMSF), Bausch Health Companies (BHC), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX) and Alnylam Pharmaceuticals (ALNY). Who are Catalent's key executives? Catalent's management team includes the folowing people: Mr. John R. Chiminski, Chairman, Pres & CEO (Age 54)Mr. Wetteny N. Joseph, Sr. VP & CFO (Age 46)Mr. Steven L. Fasman, Sr. VP, Gen. Counsel & Corp. Sec. (Age 55)Mr. William Downie, Sr. VP of Global Marketing & Sales (Age 51)Mr. Jonathan Arnold, Pres of Oral Drug Delivery Bus. Unit (Age 52) Who are Catalent's major shareholders? Catalent's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Louisiana State Employees Retirement System (0.03%), Aperio Group LLC (0.02%), Oakbrook Investments LLC (0.01%), Nisa Investment Advisors LLC (0.01%), State of Alaska Department of Revenue (0.01%) and Seven Eight Capital LP (0.01%). Company insiders that own Catalent stock include Barry Littlejohns, Christine Dolan, Donald E Morel, Jr, John R Chiminski, Lance Miyamoto, Sharon Johnson, Steven L Fasman, Uwe Roehrhoff and William Downie. View Institutional Ownership Trends for Catalent. Which major investors are buying Catalent stock? CTLT stock was purchased by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Seven Eight Capital LP, We Are One Seven LLC, Oakbrook Investments LLC, Louisiana State Employees Retirement System, Aperio Group LLC, State of Alaska Department of Revenue and Atria Investments LLC. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr and Uwe Roehrhoff. View Insider Buying and Selling for Catalent. How do I buy shares of Catalent? Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Catalent's stock price today? One share of CTLT stock can currently be purchased for approximately $41.37. How big of a company is Catalent? Catalent has a market capitalization of $6.01 billion and generates $2.46 billion in revenue each year. The company earns $83.60 million in net income (profit) each year or $1.59 on an earnings per share basis. Catalent employs 10,700 workers across the globe. What is Catalent's official website? The official website for Catalent is http://www.catalent.com. How can I contact Catalent? Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected] MarketBeat Community Rating for Catalent (NYSE CTLT)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 329 (Vote Outperform)Underperform Votes: 359 (Vote Underperform)Total Votes: 688MarketBeat's community ratings are surveys of what our community members think about Catalent and other stocks. Vote "Outperform" if you believe CTLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTLT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/22/2018 by MarketBeat.com StaffFeatured Article: What is intrinsic value?